IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor destruction, has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-day grace period until January 14, 2025, to regain compliance. During this period, ICCM's shares will continue trading on the Nasdaq Capital Market.
To regain compliance, ICCM's closing bid price must be at least $1.00 for a minimum of ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period, provided it meets other listing requirements. IceCure Medical states that maintaining its Nasdaq listing is a priority and will consider available options to cure the deficiency if necessary.
IceCure Medical (Nasdaq: ICCM), sviluppatore di tecnologia di criobrazione minimamente invasiva per la distruzione dei tumori, ha ricevuto un avviso da Nasdaq che indica la non conformità con il requisito del prezzo minimo dell'offerta di $1,00 per azione. L'azienda ha ottenuto un periodo di grazia di 180 giorni fino al 14 gennaio 2025 per riprendere la conformità. Durante questo periodo, le azioni di ICCM continueranno a essere scambiate sul Nasdaq Capital Market.
Per ristabilire la conformità, il prezzo di chiusura dell'offerta di ICCM deve essere almeno $1,00 per un minimo di dieci giorni lavorativi consecutivi. Se non riesce, l'azienda potrebbe avere diritto a un ulteriore periodo di conformità di 180 giorni, a condizione di soddisfare altri requisiti di quotazione. IceCure Medical afferma che mantenere la sua quotazione su Nasdaq è una priorità e prenderà in considerazione le opzioni disponibili per risolvere la carenza, se necessario.
IceCure Medical (Nasdaq: ICCM), desarrollador de tecnología de criablación mínimamente invasiva para la destrucción de tumores, ha recibido un aviso de Nasdaq indicando el incumplimiento del requisito de precio mínimo de oferta de $1.00 por acción. La compañía ha recibido un período de gracia de 180 días hasta el 14 de enero de 2025 para recuperar la conformidad. Durante este período, las acciones de ICCM seguirán negociándose en el Nasdaq Capital Market.
Para recuperar el cumplimiento, el precio de cierre de la oferta de ICCM debe ser al menos de $1.00 durante un mínimo de diez días hábiles consecutivos. Si no tiene éxito, la compañía puede ser elegible para un período adicional de cumplimiento de 180 días, siempre que cumpla con otros requisitos de cotización. IceCure Medical afirma que mantener su cotización en Nasdaq es una prioridad y considerará las opciones disponibles para corregir la deficiencia si es necesario.
IceCure Medical (Nasdaq: ICCM)는 종양 제거를 위한 최소 침습적 냉동 절제 기술 개발업체로서, Nasdaq으로부터 주당 $1.00의 최소 입찰 가격 요구사항을 준수하지 않았다는 통지를 받았습니다. 회사는 2025년 1월 14일까지 180일의 유예 기간을 부여받아 준수를 회복할 수 있습니다. 이 기간 동안 ICCM의 주식은 Nasdaq Capital Market에서 계속 거래될 예정입니다.
준수를 복원하려면 ICCM의 종가가 최소 10일 동안 연속으로 $1.00 이상이어야 합니다. 실패할 경우, 회사는 다른 상장 요건을 충족하는 경우 추가 180일의 준수 기간을 받을 수 있습니다. IceCure Medical은 Nasdaq 상장 유지를 최우선 과제로 삼고 있으며, 필요 시 결함을 보완하기 위한 가능한 옵션을 고려할 것입니다.
IceCure Medical (Nasdaq: ICCM), développeur de technologie de cryoablation peu invasive pour la destruction des tumeurs, a reçu un avis de Nasdaq indiquant le non-respect de l'exigence de prix d'offre minimum de 1,00 $ par action. L'entreprise a obtenu une période de grâce de 180 jours jusqu'au 14 janvier 2025 pour retrouver la conformité. Pendant cette période, les actions d'ICCM continueront à être négociées sur le Nasdaq Capital Market.
Pour regagner la conformité, le prix de clôture de l'offre d'ICCM doit être d'au moins 1,00 $ pendant au moins dix jours de bourse consécutifs. Si cela échoue, l'entreprise peut éventuellement être éligible pour une période de conformité supplémentaire de 180 jours, sous réserve de respecter d'autres exigences d'inscription. IceCure Medical déclare que le maintien de son inscription au Nasdaq est une priorité et envisagera les options disponibles pour réparer le défaut si nécessaire.
IceCure Medical (Nasdaq: ICCM), Entwickler von minimal-invasiver Kryoablationstechnologie zur Zerstörung von Tumoren, hat eine Mitteilung von Nasdaq erhalten, die auf die Nichterfüllung des Mindestgebotsanforderung von $1,00 pro Aktie hinweist. Das Unternehmen hat einen 180-tägigen Aufschub bis zum 14. Januar 2025 erhalten, um die Compliance wiederherzustellen. Während dieses Zeitraums werden die Aktien von ICCM weiterhin am Nasdaq Capital Market gehandelt.
Um wieder konform zu sein, muss der Schlusskurs von ICCM mindestens $1,00 für mindestens zehn aufeinanderfolgende Geschäftstage betragen. Bei Nichteinhaltung könnte das Unternehmen berechtigt sein, einen weiteren 180-tägigen Compliance-Zeitraum zu erhalten, vorausgesetzt, es erfüllt andere Listungsanforderungen. IceCure Medical erklärt, dass die Aufrechterhaltung der Nasdaq-Listung eine Priorität hat und dass alle verfügbaren Optionen zur Behebung des Defizits in Betracht gezogen werden, falls erforderlich.
- Granted 180-day grace period to regain compliance with Nasdaq's minimum bid price requirement
- Shares continue to trade on Nasdaq Capital Market during the compliance period
- Possibility of additional 180-day compliance period if initial period is unsuccessful
- Non-compliance with Nasdaq's minimum bid price requirement of $1.00 per share
- Risk of delisting from Nasdaq if compliance is not achieved within the given timeframe
![IceCure Medical IceCure Medical](https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg)
According to the Notice, the Company has until January 14, 2025, to regain compliance with the minimum bid price requirement. The Company can regain compliance if at any time during this 180-day period the closing bid price of its ordinary shares is at least
In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.
The Company intends to monitor the closing bid price of its ordinary shares and its continued listing on Nasdaq is a priority for the Company. Should the situation not resolve itself over the above-mentioned time frame, the Company intends to consider available options to cure the deficiency and regain compliance with the minimum bid price requirement within the compliance period.
About IceCure Medical Ltd.
IceCure Medical Ltd. (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when it discusses regaining compliance with Nasdaq's continued listing requirements, and timing and effect thereof. Because such actions deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of the Company could differ materially from those described in or implied by the statements in this press release. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-medical-announces-receipt-of-nasdaq-minimum-bid-price-notification-302201447.html
SOURCE IceCure Medical
FAQ
What is the minimum bid price requirement IceCure Medical (ICCM) must meet for Nasdaq compliance?
When is the deadline for IceCure Medical (ICCM) to regain compliance with Nasdaq's minimum bid price requirement?
How can IceCure Medical (ICCM) regain compliance with Nasdaq's minimum bid price requirement?